Epizyme (EPZM) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Epizyme Announces 2015 Financial Results and Financial Guidance
March 9, 2016 6:31 AM ESTCompany reiterates financial runway guidance through at least the end of 2017 and through major research and development milestones
Conference call to be held today at 8:00am E.T.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today highlighted certain 2015 and recent accomplishments and reported financial results for the fourth quarter of and full year 2015. In addition, earlier today, Epizyme announced a multi-year vision for the companys growth through 2020.
Key 2015... More
Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years
March 9, 2016 6:30 AM ESTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced its corporate vision and strategy through 2020. During the next five years, Epizyme will focus on four transformative activities:
Transitioning to a commercial-stage organization through the global launch of tazemetostat in patients with non-Hodgkin lymphoma (NHL) and in patients with certain genetically defined solid tumors; Expanding the clinical program for tazemetostat to support its utilization in earlier lines of therapy, in... More